RFCA
GNMX

R&F Capital Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

R&F Capital Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$157K Buy
+84,268
New +$381K 0.04% 590

Other funds holding GNMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

R&F Capital Advisors's GNMX Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Aevi Genomic Medicine Inc (GNMX) in Q1 2017: 84,268 shares worth $157K. The stake represents 0.04% of the portfolio and ranks #590 among its holdings.

73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

  • R&F Capital Advisors held 84,268 shares of Aevi Genomic Medicine Inc worth $157K as of Q1 2017.
  • Aevi Genomic Medicine Inc was a new R&F Capital Advisors position in Q1 2017.
  • Aevi Genomic Medicine Inc made up 0.04% of R&F Capital Advisors's portfolio in Q1 2017, its #590 holding.
  • 73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.